| Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours H Yao, J Lan, C Li, H Shi, JP Brosseau, H Wang, H Lu, C Fang, Y Zhang, ... Nature biomedical engineering 3 (4), 306-317, 2019 | 312 | 2019 |
| Identification of alternative splicing markers for breast cancer JP Venables, R Klinck, A Bramard, L Inkel, G Dufresne-Martin, CS Koh, ... Cancer research 68 (22), 9525-9531, 2008 | 244 | 2008 |
| RBFOX2 is an important regulator of mesenchymal tissue-specific splicing in both normal and cancer tissues JP Venables, JP Brosseau, G Gadea, R Klinck, P Prinos, JF Beaulieu, ... Molecular and cellular biology 33 (2), 396-405, 2013 | 164 | 2013 |
| Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis CP Liao, RC Booker, JP Brosseau, Z Chen, J Mo, E Tchegnon, Y Wang, ... The Journal of clinical investigation 128 (7), 2848-2861, 2018 | 127 | 2018 |
| Alternative splicing of SYK regulates mitosis and cell survival P Prinos, D Garneau, JF Lucier, D Gendron, S Couture, M Boivin, ... Nature structural & molecular biology 18 (6), 673-679, 2011 | 119 | 2011 |
| High-throughput quantification of splicing isoforms JP Brosseau, JF Lucier, E Lapointe, M Durand, D Gendron, J Gervais-Bird, ... Rna 16 (2), 442-449, 2010 | 96 | 2010 |
| Spatiotemporal Loss of NF1 in Schwann Cell Lineage Leads to Different Types of Cutaneous Neurofibroma Susceptible to Modification by the Hippo Pathway Z Chen, J Mo, JP Brosseau, T Shipman, Y Wang, CP Liao, JM Cooper, ... Cancer discovery 9 (1), 114-129, 2019 | 68 | 2019 |
| Tumor microenvironment–associated modifications of alternative splicing JP Brosseau, JF Lucier, H Nwilati, P Thibault, D Garneau, D Gendron, ... Rna 20 (2), 189-201, 2014 | 64 | 2014 |
| NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation JP Brosseau, CP Liao, Y Wang, V Ramani, T Vandergriff, M Lee, A Patel, ... Nature communications 9 (1), 5014, 2018 | 52 | 2018 |
| Trametinib induces neurofibroma shrinkage and enables surgery P Vaassen, N Dürr, A Röhrig, R Willing, T Rosenbaum Neuropediatrics 50 (05), 300-303, 2019 | 48 | 2019 |
| Redirecting splicing with bifunctional oligonucleotides JP Brosseau, JF Lucier, AA Lamarche, L Shkreta, D Gendron, E Lapointe, ... Nucleic acids research 42 (6), e40-e40, 2014 | 41 | 2014 |
| The biology of cutaneous neurofibromas: consensus recommendations for setting research priorities JP Brosseau, DC Pichard, EH Legius, P Wolkenstein, RM Lavker, ... Neurology 91 (2_Supplement_1), S14-S20, 2018 | 38 | 2018 |
| 8‐BuS‐ATP derivatives as specific NTPD ase1 inhibitors J Lecka, I Gillerman, M Fausther, M Salem, MN Munkonda, JP Brosseau, ... British Journal of Pharmacology 169 (1), 179-196, 2013 | 33 | 2013 |
| A peptidic inhibitor for PD-1 palmitoylation targets its expression and functions H Yao, C Li, F He, T Song, JP Brosseau, H Wang, H Lu, C Fang, H Shi, ... RSC Chemical Biology 2 (1), 192-205, 2021 | 32 | 2021 |
| Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing JP Brosseau, AA Sathe, Y Wang, T Nguyen, DA Glass, C Xing, LQ Le Acta Neuropathologica Communications 9, 1-11, 2021 | 30 | 2021 |
| Translating current basic research into future therapies for neurofibromatosis type 1 JP Brosseau, CP Liao, LQ Le British journal of cancer 123 (2), 178-186, 2020 | 26 | 2020 |
| Targeted degradation of immune checkpoint proteins: emerging strategies for cancer immunotherapy J Xu, JP Brosseau, H Shi Oncogene 39 (48), 7106-7113, 2020 | 23 | 2020 |
| Spatiotemporal loss of NF1 in schwann cell lineage leads to different types of cutaneous neurofibroma susceptible to modification by the hippo pathway. Cancer Discov. 2019; 9 … Z Chen, J Mo, JP Brosseau, T Shipman, Y Wang, CP Liao, JM Cooper, ... CD-18-0151.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 17 | |
| Toward understanding the mechanisms of malignant peripheral nerve sheath tumor development T Mohamad, C Plante, JP Brosseau International Journal of Molecular Sciences 22 (16), 8620, 2021 | 14 | 2021 |
| Schwannoma development is mediated by Hippo pathway dysregulation and modified by RAS/MAPK signaling Z Chen, S Li, J Mo, E Hawley, Y Wang, Y He, JP Brosseau, T Shipman, ... JCI insight 5 (20), 2020 | 14 | 2020 |
